US Stocks
/
TScan Therapeutics, Inc. Share Price

TScan Therapeutics, Inc. Share Price

NASDAQ: TCRX | Micro Cap
$0.31
-$0.01 (-4.01%) Last updated on 19 Sep, 2026 | 01:25 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

TScan Therapeutics, Inc. Stock Performance

Open
$0.34
Prev. Close
$0.33
Circuit Range
N/A
Day Range
$0.31 - $0.34
Year Range
$0.29 - $2.56
Volume
10,298
Average Traded
$0.32

TScan Therapeutics, Inc. Share Price Today

As of 20 September 2026, TScan Therapeutics, Inc.'s share price is $0.31. The stock opened at $0.34, compared to its previous close of $0.33. During today's trading session, TScan Therapeutics, Inc.'s share price traded between $0.31 and $0.34, with an average price of $0.33. Over the past 52 weeks, the stock has recorded a high of $2.56 and a low of $0.29. In terms of performance, TScan Therapeutics, Inc.'s share price has declined by 68.75% over the last six months and is down 82.28% on a year-on-year basis.

TScan Therapeutics, Inc. Share Price Chart

$0.31$0.34
L
Show Current Price
H

TScan Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$40.71M
PE Ratio (TTM)
-0.31
Dividend Yield
N/A
EPS (TTM)
$-1.00
Revenue (TTM)
$10.32M
Return On Equity (TTM)
-105.40%
Profit Margin
-1256.81%
Debt to Equity
0.15
Quarterly Earnings Growth YoY
-19.48%

TScan Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsMar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025
RevenueN/A$536000.00$1.05M$2.17M$3.08M$2.51M
Net Profit-$30.14M-$31.66M-$29.89M-$34.13M-$36.95M-$35.71M
Net Profit MarginN/A-5906.90%-2849.09%-1571.95%-1201.30%-1422.14%
Income ChangeN/A-5.04%5.60%-14.19%-8.28%3.36%

TScan Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars202220242025
Revenue$13.54M$2.82M$10.32M
Net Profit-$66.22M-$127.50M-$129.77M
Net Profit Margin-489.26%-4527.66%-1256.81%
Income ChangeN/A-92.54%-1.78%

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics, Inc. Historical Returns

MonthOpenCloseChange %
Sep 2026
$0.71
$0.32
-58.33%
Aug 2026
$0.75
$0.76
+1.34%
Jul 2026
$1.02
$0.75
-23.88%
Jun 2026
$1.07
$0.98
-9.68%
May 2026
$1.14
$1.08
-7.26%
Apr 2026
$1.04
$1.17
+16.53%
Mar 2026
$1.07
$1.00
-5.73%
Feb 2026
$1.04
$1.06
+3.90%
Jan 2026
$1.00
$1.02
+3.02%
Dec 2025
$1.11
$0.99
-11.16%
Nov 2025
$1.44
$1.12
-42.27%
Oct 2025
$1.83
$1.94
+9.60%

TCRX Share Price FAQs

What is TScan Therapeutics, Inc. share price today?

chevron-up
TScan Therapeutics, Inc. share price today is $0.31 as on September 19, 2026 at 1:25 am IST.

What is the 52 week high and 52 week low of TScan Therapeutics, Inc. stock?

chevron-up
The 52 week high of TScan Therapeutics, Inc. stock is $2.56, while the 52 week low is $0.29 as of 19 Sep '26.

What is TCRX's market capitalisation today?

chevron-up
TCRX market capitalisation is $40.71M as of September 20, 2026, at 4:37 pm IST.

What is TCRX's net income for the last quarter?

chevron-up
TCRX's net income for the last quarter is -0.04B USD.

What is the 5 year returns of TCRX?

chevron-up
The 5 year returns of TCRX is -96.24% as on 19 Sep '26.

What is the high & low stock price of TCRX today?

chevron-up
TCRX stock price hit a high of $0.34 and low of $0.31 as of 19 Sep '26.

Can I buy TCRX shares in India?

chevron-up
Yes. You can buy TCRX in India by opening an international trading account.